Erchonia has rolled out the Zerona body-contouring laser device in the SAARC region.
Erchonia Asia, a subsidiary of AVI Pharma, will market the Zerona laser device all over the SAARC region. The US FDA recently approved the Zerona laser, which is a painless, invasive treatment for fat removal.
The Zerona device features six treatments with a single 40-minute treatment each day for a period of two weeks. Zerona proved its efficiency through a multi-site, double blind, placebo controlled study. The device guarantees an average reduction of three inches in two weeks.
Zerona, in the pilot studies, has shown to enhance sensitivity to leptin, a hunger-hormone. The sensitivity reduces the appetite for patients and helps in modifying their diet.
The Zerona unit generates a low-level output, which has no thermal effects on the tissues of the body. The unique technology of the Zerona does not damage or kill fat cells, but develops a pore in every cell for the fat to move out. Its external application offers results without the dangers connected with weight loss surgery. The procedure has no negative side effects and has no downtime.